RxDoctor Payments Data

Prixit Sharma, MD

Internal Medicine · Avon Park, FLNPI 1003803156

Payments from drug & device makers

$1,055in general payments, 2019–2025

Across 57 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$211
  • GSK$119
  • Lilly USA, LLC$118
  • AstraZeneca$95
  • Amgen$73
  • Otsuka America Pharmaceutical, Inc.$51
  • plus $389 from 16 others

What the payments were for

  • Food & beverage$1,055100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,055 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$221,508
Medicare patients
721
Services billed
2,490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban239$277,698
OzempicSemaglutide156$243,040
MounjaroTirzepatide155$189,712
JardianceEmpagliflozin161$177,414
JanuviaSitagliptin Phosphate130$154,132
Trelegy ElliptaFluticasone/Umeclidin/Vilanter131$126,600
AustedoDeutetrabenazine11$124,066
EntrestoSacubitril/Valsartan35$59,460
XareltoRivaroxaban40$52,005
TrulicityDulaglutide50$50,726
TradjentaLinagliptin19$23,429
Breo ElliptaFluticasone/Vilanterol36$22,473
FarxigaDapagliflozin Propanediol12$18,309
Spiriva HandihalerTiotropium Bromide23$16,318
Combivent RespimatIpratropium/Albuterol Sulfate12$14,477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$211$243,040156 claims
Lilly USA, LLCMounjaro, Trulicity$118$240,439205 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$18$215,320192 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$119$156,152182 claims
MerckJanuvia$16$154,132130 claims
Teva Pharmaceuticals USA, Inc.Austedo$29$124,06611 claims
Johnson & JohnsonXarelto$19$52,00540 claims
AstraZenecaFarxiga, Symbicort$95$30,16046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Avon Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →